Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491478 | 1.00 | CACNA1B (0.45) | CACNA1BEPHX1AAK1GAAHDAC4 | |
| SCHEMBL1372066 | 0.87 | AAK1 (0.48) | CACNA1BEPHX1AAK1GAAHDAC4 | |
| SCHEMBL1372065 | 0.87 | AAK1 (0.48) | CACNA1BEPHX1AAK1GAAHDAC4 | |
| SCHEMBL21904477 | 0.87 | AAK1 (0.48) | CACNA1BEPHX1AAK1GAAHDAC4 | |
| SCHEMBL24103813 | 0.85 | AAK1 (0.49) | CACNA1BEPHX1AAK1GAAHDAC4 | |
| SCHEMBL29090746 | 0.85 | AAK1 (0.49) | CACNA1BEPHX1AAK1GAAHDAC4 | |
| SCHEMBL30878159 | 0.85 | AAK1 (0.49) | CACNA1BEPHX1AAK1GAAHDAC4 | |
| SCHEMBL28854870 | 0.82 | CACNA1B (0.47) | CACNA1BEPHX1GAAHDAC4HDAC1 | |
| SCHEMBL23270360 | 0.82 | CACNA1B (0.47) | CACNA1BEPHX1GAAHDAC4HDAC1 | |
| SCHEMBL5322434 | 0.82 | CACNA1B (0.47) | CACNA1BEPHX1GAAHDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013175-B9 | p38 MAP KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2020-11-11 | — | — | EP | disclosed |
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| EP-1879895-B1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-06-08 | — | — | EP | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| EP-2301939-A1 | Enzyme inhibitors | Chroma Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| EP-1879895-A1 | ENZYME INHIBITORS | Chroma Therapeutics Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | CACNA1B 4367/4885EPHX1 2631/4885AAK1 2891/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | CACNA1B 3073/4885EPHX1 605/4885AAK1 4545/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | CACNA1B 3503/4885EPHX1 1410/4885AAK1 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.